We Are Not Surprised That J&J May Be Selling Off Cordis

The segment's growth has slowed down significantly and the company is looking at ways to downsize this segment and focus more on growing pharmaceutical business. Strong pricing pressure and competition from lesser known names appears to be the primary factor behind the stunted growth. Last year, J&J sold its diagnostics unit, Ortho-Clinical Diagnostics, to the Carlyle group for around $4 billion. The divestitures may continue and this year it could be Cordis that is to go.